CN1234367C - 用于压迫性尿失禁治疗的芳基偶氮－取代的咪唑 - Google Patents
用于压迫性尿失禁治疗的芳基偶氮－取代的咪唑 Download PDFInfo
- Publication number
- CN1234367C CN1234367C CNB028129687A CN02812968A CN1234367C CN 1234367 C CN1234367 C CN 1234367C CN B028129687 A CNB028129687 A CN B028129687A CN 02812968 A CN02812968 A CN 02812968A CN 1234367 C CN1234367 C CN 1234367C
- Authority
- CN
- China
- Prior art keywords
- imidazoles
- azo
- chloro
- arylazo
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 238000011282 treatment Methods 0.000 title claims abstract description 9
- 206010066218 Stress Urinary Incontinence Diseases 0.000 title claims abstract description 8
- 150000002460 imidazoles Chemical class 0.000 title abstract description 6
- -1 5-chloro-2-methoxyphenyl Chemical group 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 7
- 208000022170 stress incontinence Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001800 adrenalinergic effect Effects 0.000 abstract description 4
- 230000004936 stimulating effect Effects 0.000 abstract description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 13
- 229960002748 norepinephrine Drugs 0.000 description 13
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
- 239000000556 agonist Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003975 mesenteric artery Anatomy 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 210000001635 urinary tract Anatomy 0.000 description 4
- 230000008484 agonism Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960002892 adrenalone Drugs 0.000 description 1
- PZMVOUYYNKPMSI-UHFFFAOYSA-N adrenalone Chemical compound CNCC(=O)C1=CC=C(O)C(O)=C1 PZMVOUYYNKPMSI-UHFFFAOYSA-N 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0114008.6A GB0114008D0 (en) | 2001-06-08 | 2001-06-08 | New therapautic use |
| GB0114008.6 | 2001-06-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1541099A CN1541099A (zh) | 2004-10-27 |
| CN1234367C true CN1234367C (zh) | 2006-01-04 |
Family
ID=9916211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB028129687A Expired - Fee Related CN1234367C (zh) | 2001-06-08 | 2002-06-07 | 用于压迫性尿失禁治疗的芳基偶氮－取代的咪唑 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20040242547A1 (enExample) |
| EP (1) | EP1399167A1 (enExample) |
| JP (1) | JP2005500285A (enExample) |
| KR (1) | KR20040030654A (enExample) |
| CN (1) | CN1234367C (enExample) |
| AU (1) | AU2002311445B2 (enExample) |
| BR (1) | BR0210195A (enExample) |
| CA (1) | CA2449957A1 (enExample) |
| GB (1) | GB0114008D0 (enExample) |
| MX (1) | MXPA03011226A (enExample) |
| RU (1) | RU2004100228A (enExample) |
| WO (1) | WO2002100414A1 (enExample) |
| ZA (1) | ZA200309473B (enExample) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6056123B2 (ja) * | 1979-07-30 | 1985-12-09 | 持田製薬株式会社 | 浮腫・低血圧・心不全および粘膜充血治療用剤 |
| DE19514579A1 (de) * | 1995-04-20 | 1996-10-24 | Boehringer Ingelheim Kg | Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz |
| US6323231B1 (en) * | 2000-02-17 | 2001-11-27 | Abbott Laboratories | Use of α1A adrenoceptor agonists with α1B and α1D antagonism for the treatment of stress urinary incontinence |
-
2001
- 2001-06-08 GB GBGB0114008.6A patent/GB0114008D0/en not_active Ceased
-
2002
- 2002-06-07 WO PCT/GB2002/002635 patent/WO2002100414A1/en not_active Ceased
- 2002-06-07 MX MXPA03011226A patent/MXPA03011226A/es unknown
- 2002-06-07 AU AU2002311445A patent/AU2002311445B2/en not_active Ceased
- 2002-06-07 EP EP02738362A patent/EP1399167A1/en not_active Withdrawn
- 2002-06-07 BR BR0210195-5A patent/BR0210195A/pt not_active IP Right Cessation
- 2002-06-07 JP JP2003503235A patent/JP2005500285A/ja not_active Withdrawn
- 2002-06-07 CA CA002449957A patent/CA2449957A1/en not_active Abandoned
- 2002-06-07 CN CNB028129687A patent/CN1234367C/zh not_active Expired - Fee Related
- 2002-06-07 KR KR10-2003-7015978A patent/KR20040030654A/ko not_active Withdrawn
- 2002-06-07 ZA ZA200309473A patent/ZA200309473B/xx unknown
- 2002-06-07 RU RU2004100228/15A patent/RU2004100228A/ru not_active Application Discontinuation
- 2002-06-07 US US10/478,977 patent/US20040242547A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005500285A (ja) | 2005-01-06 |
| ZA200309473B (en) | 2005-03-23 |
| RU2004100228A (ru) | 2005-06-10 |
| EP1399167A1 (en) | 2004-03-24 |
| AU2002311445B2 (en) | 2005-08-25 |
| CA2449957A1 (en) | 2002-12-19 |
| WO2002100414A1 (en) | 2002-12-19 |
| CN1541099A (zh) | 2004-10-27 |
| GB0114008D0 (en) | 2001-08-01 |
| US20040242547A1 (en) | 2004-12-02 |
| BR0210195A (pt) | 2004-07-27 |
| MXPA03011226A (es) | 2004-03-26 |
| KR20040030654A (ko) | 2004-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Witteveen et al. | Quantitation of infarct size in man by means of plasma enzyme levels. | |
| JP2002531505A (ja) | 糖脂質蓄積症を治療する薬物製造のためのデオキシノジリマイシンの長鎖ｎ−アルキル誘導体の使用 | |
| US4973603A (en) | Platelet activating factor antagonist and methods of use therefor | |
| Korkmaz-Icöz et al. | Administration of zinc complex of acetylsalicylic acid after the onset of myocardial injury protects the heart by upregulation of antioxidant enzymes | |
| US5217962A (en) | Method and composition for treating psoriasis | |
| Bounous et al. | Acute necrosis of the intestinal mucosa with high serum levels of diamine oxidase | |
| CN1234367C (zh) | 用于压迫性尿失禁治疗的芳基偶氮－取代的咪唑 | |
| AU672243B2 (en) | A method of increasing adenosine excretion | |
| RU2388466C2 (ru) | Производные феноксиалкилкарбоновых кислот при лечении воспалительных заболеваний | |
| Lindell et al. | The effect of enzyme inhibitors on histamine catabolism in man | |
| Kendall | Clinical trial data on the cardioprotective effects of beta-blockade | |
| CN1047520C (zh) | 降低血脂水平的药物 | |
| CN1097457C (zh) | 对活性氧组份不良反应的治疗和预防 | |
| US20040105906A1 (en) | Antiagionecic, antitumor, chemopreventative agents | |
| Ward et al. | Effects of thrombolytic regimen, early catheterization, and predischarge angiographic variables on six-week left ventricular function | |
| AU2002311445A1 (en) | Arylazo-substituted imidazole for the treatment of stress urinary incontinence | |
| RU2648470C2 (ru) | Способ оптимизации лечения женщин кардиотропной терапией и заместительной гормональной терапией при эстрогенодефиците с артериальной гипертензией в позднем репродуктивном периоде | |
| Pollitt | Update on the pathophysiology of laminitis. | |
| RU2851671C1 (ru) | Способ прогнозирования неблагоприятного исхода острого коронарного синдрома у пациентов с постковидным синдромом | |
| Liao | Arterial stiffness and the development of hypertension | |
| RU2249210C2 (ru) | Способ прогнозирования предрасположенности к развитию и тяжести течения деформирующего остеоартроза коленного сустава у взрослых | |
| CN120983437A (zh) | Diphenylalazine A在制备抗血栓药物中的应用 | |
| CN115671097A (zh) | 用于防治动脉粥样硬化及斑块不稳定性的化合物及其应用 | |
| Yamakado et al. | Regression of left ventricular hypertrophy with long‐term treatment of nifedipine in systemic hypertension | |
| Keiser et al. | Comparative Assessment of Peripheral Stent Abrasiveness under Cyclic Deformations Experienced During Limb Flexion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |